EPA may increase the efficacy and/or reduce ribavirin-associated hemolytic anemia in patients being treated for chronic hepatitic C virus infection.

Your email address will not be published. Required fields are marked *

Comment *

Name *

Email *

Website

Save my name, email, and website in this browser for the next time I comment.